The 2011 Leading Life Science Intermediates Companies Product Portfolio Analyses

October 2010 | 57 pages | ID: L9719A03D12EN
Venture Planning Group

Abstracts

Global PDF: US$ 3,900.00

For each company, the analyses present:

• Extensive review of the major product lines.
• New product introductions and line extensions.

The companies analyzed in the report: BASF, Bayer/Lanxess, Cambrex, Clariant, DowPharma, DSM, Evonik, Lonza, Novasep, and Rhodia.

Contains 57 pages